Clinical utilities of platelet-derived growth factor signaling in breast cancer
Pharmacological Research · 2026-09 · 231 · 108372
DOI: 10.1016/j.phrs.2026.108372 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026-09. Verfasst von Jesse J Reardon und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Radiation Oncology, The Ohio State University, Col…. Hauptthemen laut MEDLINE: Breast Neoplasms, Platelet-Derived Growth Factor, Receptors, Platelet-Derived Growth Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, California Breast Cancer Research Program, National Institutes of Health.
Abstract (Originalsprache)
Platelet-derived growth factors (PDGFs) and their cognate receptors (PDGFRα/β) play critical roles in breast cancer progression and metastasis. This review summarizes current evidence of PDGF ligand and receptor expression patterns, oncogenic functions, prognostic significance and therapeutic targetability, with a specific focus on small molecule inhibition. PDGF-PDGFR signaling is known to contribute to epithelial to mesenchymal transition, cancer stem cell maintenance, desmoplasia, angiogenesis, and immune modulation. Additionally, the four PDGF ligands have distinct oncogenic functions. PDGFA and PDGFB have been implicated in breast cancer associated brain metastasis, while PDGFC has been shown to play a crucial role in fibroblast activation. PDGFD, while less studied, may activate epithelial to mesenchymal transition in breast cancer. High expression of PDGFA, PDGFB, PDGFC, and stromal PDGFRβ correlate with poor patient survival, highlighting their potential as candidate biomarkers. We specifically focus on evaluating current therapeutic strategies which target the PDGF-PDGFR axis, including neutralizing antibodies, aptamers, and small molecule inhibitors, which show preclinical promise but limited clinical success in breast cancer to date. We discuss future research directions with emphasis on identifying selective inhibitors, utilizing PDGF-PDGFR signaling components for patient stratification, and combination with immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Radiation Oncology, The Ohio State University, Columbus, Ohio 43210, USA.
- The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Department of Radiation Oncology, The Ohio State University, Columbus, Ohio 43210, USA. Electronic address: gina.sizemore@osumc.edu.
Förderung
- NCI NIH HHS
- California Breast Cancer Research Program
- National Institutes of Health
Zitieren
APA
Reardon, J. J., Mossing, A. A., Packard, R. L., Shah, S., & Sizemore, G. M. (2026). Clinical utilities of platelet-derived growth factor signaling in breast cancer. Pharmacological Research, 231, 108372. https://doi.org/10.1016/j.phrs.2026.108372
Vancouver
Reardon JJ, Mossing AA, Packard RL, Shah S, Sizemore GM. Clinical utilities of platelet-derived growth factor signaling in breast cancer. Pharmacological Research. 2026;231:108372. doi:10.1016/j.phrs.2026.108372
BibTeX
@article{Reardon2026,
author = {Reardon, Jesse J and Mossing, Alexis A and Packard, Rebecca L and Shah, Sajita and Sizemore, Gina M},
title = {Clinical utilities of platelet-derived growth factor signaling in breast cancer},
journal = {Pharmacological Research},
year = {2026},
volume = {231},
pages = {108372},
doi = {10.1016/j.phrs.2026.108372}
}
EUVIMED